Skip to main content

Lactation

0
Pipeline Programs
4
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Providence Therapeutics
1 program
Heat exposureN/A1 trial
Active Trials
NCT07036640Recruiting10Est. May 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Injected GLP-1 Receptor Agonists and Dual AgonistsN/A1 trial
Active Trials
NCT07720414Recruiting18Est. Jun 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
Colorado TherapeuticsInjected GLP-1 Receptor Agonists and Dual Agonists
Providence TherapeuticsHeat exposure

Clinical Trials (2)

Total enrollment: 28 patients across 2 trials

NCT07720414Colorado TherapeuticsInjected GLP-1 Receptor Agonists and Dual Agonists

Effects of GLP-1 RAs on Human Lactation Outcomes

Start: Jul 2026Est. completion: Jun 202818 patients
N/ARecruiting

The Impact of Acute Exercise in the Heat on Breast Milk Production and Composition in Lactating Women

Start: Jul 2025Est. completion: May 202610 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 28 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.